{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Peripheral blood mononuclear cells', 'Quality of life assessments', 'Statistical Plan', 'The primary os endpoint will be tested in patients with SCC first. If the', 'null hypothesis is rejected in the SCC patients, then os will be tested in the', 'overall population. The sample size and power are calculated using', 'East version 6.4.1 statistical software.', 'The sponsor assumes a median os of 7 months for SCC patients treated with', 'IC chemotherapy and a median os of 10 months for SCC patients treated', 'with cemiplimab. The assumptions correspond to an approximately 42.8%', 'increase in median os and a hazard ratio (HR) of 0.7 if os is distributed', 'exponentially in both treatment groups.', 'Two interim efficacy analyses are planned using Lan-DeMets', \"(O'Brien-Fleming) spending function at 70% and 85% of the total\", 'os events, respectively. A total of 340 os events in SCC patients will yield', 'approximately 90% power to detect an HR of 0.7 with an overall type I error', 'of 0.025 (1-sided). The first interim efficacy analysis will be performed', 'after observing approximately 238 os events (70% of total os events). It', 'is projected that an observed HR of 0.729 or lower would result in', 'a', 'statistically significant improvement in os at the 1-sided nominal type I', 'error of 0.0074 at the first interim efficacy analysis. The second interim', 'efficacy analysis will be performed after observing approximately 289 os', 'events (85% of total os events). It is projected that an observed HR of 0.769', 'or lower would result in a statistically significant improvement in os at the', '1-sided nominal type I error of 0.0129 at the second interim efficacy', 'analysis. The final efficacy analysis will be performed after observing', 'approximately 340 os events. It is projected that an observed HR of 0.801', 'or lower would result in a statistically significant improvement in os at the', '1-sided nominal type I error of 0.0202 at the final analysis. The actual alpha', 'spending will be based on the actual number of os events included in the', \"analyses and determined by the O'Brien-Fleming spending function at the\", 'time of interim and final analyses.', 'Considering the enrollment rate (2 patients/month for months 1 to 5,', '9 patients/month for months 6 to 16, 20 patients/month for months 17 to 23,', '22 patients/month for month 24 and beyond) and 10% dropout rate per year,', 'enrollment of 460 randomized SCC patients will yield 340 os events', 'approximately 42 months after the first SCC patient is randomized.', 'At the time when 460 SCC patients are enrolled in the study, a total', 'enrollment in the study of approximately 590 patients is projected (SCC +', 'non-SCC). The actual number of patients to be enrolled will depend on the', 'proportion of adenocarcinoma patients in the patient population and the time', 'when Amendment 5 is implemented at each of the study sites. If the HR is', '0.7, the power for testing os in the overall population will be higher than', '90%.', 'Regeneron Pharmaceuticals, Inc.', 'Page 30 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'The primary endpoint of os will be analyzed in patients with SCC first by', 'stratified log-rank test using geographic region (North America versus Asia', 'versus Rest of World [ROW]) as a stratification factor. The HR and its 95%', 'confidence interval (CI) will be estimated by a stratified Cox regression', 'model using the treatment as covariate.', 'If the final analysis of os is statistically significant in the SCC patients, then', 'the analysis of os will be performed in the overall population by stratified', 'log-rank test using histology and geographic region. If statistically', 'significant, the secondary endpoints PFS and ORR will be tested using a', 'hierarchical procedure. The order of hierarchical testing for secondary', 'endpoints will be specified in the statistical analysis plan (SAP) before', 'database lock (DBL).', 'Analysis of PFS and ORR will be performed at the time of os analysis. The', 'PFS will be analyzed using the same statistical method as the analysis of', 'OS. The ORR will be analyzed using Cochran-Mantel-Haenszel test', 'stratified by the same stratification factors used in analysis of OS. An', 'associated odds ratio and 95% CI will be calculated. Objective response', 'rate and the corresponding 95% exact CI will be calculated by the Clopper-', 'Pearson method for each treatment arm.', 'The change in EORTC QLQ-C30 scores from baseline to the end of the', 'study will be summarized descriptively at each post-baseline time point and', 'compared using a mixed effect model, if appropriate.', 'Safety observations and measurements including drug exposure, AEs,', 'laboratory data, vital signs, and Eastern Cooperative Oncology Group', 'performance status will be summarized and presented in tables and listings.', 'Regeneron Pharmaceuticals, Inc.', 'Page 31 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}